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Dear Sirs,
The coronavirus (COVID-19) pandemic has influenced 
psychological and physical health of the general popula-
tion [1] with chronic patients mostly suffering for public 
health-care reconfiguration [2]. We aimed at evaluating the 
impact of this event on a cohort of Italian amyotrophic lat-
eral sclerosis (ALS) patients and caregivers. Patients suffer-
ing from respiratory involvement and those with functional 
disability or rapid progression were expected to have major 
concern of being infected by COVID-19. To this account, 
30 ALS patients and 29 caregivers underwent longitudinal 
assessment by remote consulting between 18 March and 2 
May. None had COVID-19. They compiled questionnaires 
assessing pandemic distress (Table 1), mood, loneliness, 
caregiver burden (CBI), and behavioural changes (Table 2). 
All participants gave informed consent and the local Ethical 
Committee approved the study. Spearman rho correlations 
(Bonferroni correction, p ≤ 0.003) and Mann–Whitney U 
tests (p < 0.01) were performed to verify if COVID-19 dis-
tress was related to clinical and neuropsychological profiles. 
Surprisingly, we did not find significant association between 
worries of getting COVID-19 and functional disease sever-
ity, stage or clinical phenotypes. Instead, it was the feeling of 
loneliness to play a major role in the fear of getting the infec-
tion (rho = 0.672, p < 0.001), confirming that social isolation 
and loneliness are among the most important adverse conse-
quences of the pandemic in ALS patients [3]. Additionally, 
anxiety was associated with the degree of feelings of being 
forgotten/rejected by clinicians (rho = 0.543, p = 0.002) and 
change in neurologist–patient relationship (rho = 0.536, 
p = 0.003). Anxious patients were among the most vulnera-
ble ones to suffer from the change of the health-care system. 
During the pandemic, indeed, many Italian institutions deliv-
ered services remotely, possibly coordinating telemedicine 
activities [4]. However, telematics support for ALS patients 
should take into consideration the presence of cognitive 
and behavioural impairment. Between-group comparison 
revealed that cognitive/behavioural impaired patients, diag-
nosed according to the consensus criteria [5], did not aug-
ment the use of social network to be in touch with relatives 
and friend during lockdown (U = 49.5, p = 0.009), possibly 
due to difficulties in using electronic devices. Moreover, 
self-rate of behavioural change due to COVID-19 (overall 
sum of E subscale, Table 1) was inversely related to dimen-
sional apathy scale (DAS) scores (rho = − 0.576, p = 0.001), 
documenting that apathetic patients reported even minor 
behavioural changes during the pandemic. These findings 
are in keeping with low awareness in behaviourally impaired 
patients [5]. Patients’ behavioural alterations and motor disa-
bility were the greatest burden for caregivers [6], rather than 
the concern of getting COVID-19 or limitations of daily life 
due to the quarantine. CBI was indeed associated only with 
patient disability (ALSFRS-R, rho = − 0.660, p < 0.001) 
and apathy (DAS, rho = 0.557, p = 0.002). In caregivers, 
pandemic distress was documented only as a change in the 
degree of anxiety possibly due to the greater amount of time 
spent in the house during lockdown (rho = 0.539, p = 0.003). 
Interestingly, patients and caregivers gave similar answers to 
the questionnaire on the changes that COVID-19 caused in 
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daily life. It could be speculated that families accustomed to 
manage degenerative diseases are more resilient to changes 
in whatever form they occur. Although the long‐term impact 
of the COVID‐19 pandemic is yet to be determined, our 
study suggests that families with ALS patients, mostly if 
suffering also form cognitive/behavioural impairment, have 
higher level of anxiety and feeling of loneliness, and are par-
ticularly vulnerable to distress. Tailored interventions should 
be considered to help them in facing better the changes in 
habits and health-care system. 
Table 1  Evaluation of the impact of COVID-19 on ALS disease management and daily life
Data are expressed as means (± standard deviation; range min–max)
n.a. not available data, n.s. not significant difference
a The perceived risk index was calculated summing z standard scores of the A(1–3) responses
b The range of responses varied from 1 (not at all) to 5 (extremely)
Questionnaire ALS patients Caregivers Between 
group differ-
ences
(A) Perceived risk of COVID-19 (index score)a − 0.254 (1.5) 0.285 (1.8) n.s
(1) How much are you able to avoid COVID-19?b 4.00 (0.8; range 3–5) 3.78 (1.2; range 1–5) n.s
(2) Amount of information sources on COVID-19 (min 0; max 8) 3.53 (1.3; range 1–6) .18 (1.5; range 1–6) n.s
(3) # actions taken to avoid SARS-Cov-2 contagion (min 0–max 9) 8.16 (1.0; range 4–9) 8.44 (0.8; range 6–9) n.s
(B) Concern about COVID-19
(1) Worries in the event of an infection b 3.53 (1.4; range 1–5) 3.21 (1.6; range 1–5) n.s
(2) Thinking of COVID-19b 3.10 (1.2; range 1–5) 2.96 (1.2; range 1–5) n.s
(3) Thinking that COVID-19 can worry my  familyb 3.70 (0.9; range 2–5) 3.50 (1.3; range 1–5) n.s
(C) Change in disease management
(1) Drug management  changeb 1.30 (0.9; range 1–5) n.a –
(2) Change in neurologist-patient  relationshipb 1.96 (1.4; range 1–5) n.a –
(3) Feelings of being forgotten/rejected by  cliniciansb 1.46 (0.8; range 1–4) n.a –
(4) Concern about negative consequences of COVID-19 healthy emer-
gency on the management of the disease by  cliniciansb
2.65 (1.3; range 1–5) n.a –
(D) Change in habits due to COVID-19 state of emergency
(1) Out-of-home  habitsb 3.56 (1.4; range 1–5) 3.79 (1.2; range 1–5) n.s
(2) Household  habitsb 1.90 (1.2; range 1–5) 2.21 (1.2; range 1–5) n.s
(3) Use of social  networksb 2.23 (1.5; range 1–5) 2.38 (1.3; range 1–5) n.s
(4) Work/Retirementb 2.83 (1.5; range 1–5) 2.62 (1.8; range 1–5) n.s
(5) Personal care b 2.03 (0.9; range 1–5) 1.93 (1.3 range 1–5) n.s
(E) Change in behaviour due to COVID-19 state of emergency
(1) Irritable/Nervousb 1.66 (1.1; range 1–5) 1.78 (0.8; range 1–4) n.s
(2) Agitated/Anxiousb 1.50 (0.7 range 1–4) 1.78 (0.9; range 1–5) n.s
(3) Sad/Depressedb 1.46 (0.7; range 1–3) 1.60 (0.8; range 1–4) n.s
(4)  Boredb 1.89 (1.1; range 1–4) 2.03 (1.0; range 1–4) n.s
(5) Increased consumption of alcohol/cigarettesb 1.13 (0.5; range 1–4) 1.25 (0.6; range 1–4) n.s
(6) Increased food  consumptionb 1.46 (0.8; range 1–4) 1.64 (0.9 range 1–5) n.s
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 Age 61.26 (13.0) 56.29 (12.1) n.s
 Male/female 14/16 13/16 n.s
 Educational level (min 0; max 9) 3.83 (1.7; range 1–7) 3.53 (1.5; range 1–7) n.s
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 From Northern/Southern Italy 22/8 22/7 n.s
Clinical data
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Neuropsychological data
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 HADS-MND anxiety 4.00 (3.25; range 0–10) n.a –
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 QoL—WhoQol-Age 48.23 (10.5) 51.89 (8.0) n.s
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